AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02577289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
Description: platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
Study NCT04208815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk Fat
Description: Effects of the addition of 20 g milk fat.
Study NCT04208815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk Fat
Description: Effects of the addition of 20 g milk fat.
Study NCT00995332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine, all-trans retinoic acid, valproic acid
Description: ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
Study NCT02903927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CT LUCIA IOL
Study NCT02903927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Acrysof IQ SN60WF IOL
Study NCT02755233 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function
Description: Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
Study NCT03828656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
Study NCT00303316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study NCT00303316 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study NCT03508362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fRMI)
Description: Acquisition of a functional MRI on the sub thalamic nucleus
Study NCT03508362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fRMI)
Description: Acquisition of a functional MRI on the sub thalamic nucleus
Study NCT01925742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated prenatal screening for Down's syndrome
Description: Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
Study NCT02705365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
Study NCT02385773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTM202
Description: Administration of study nutritional product once per day for 3 days starting immediately after enrollment
Study NCT02385773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enfamil Puramino
Description: Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
Study NCT03869619 — intervention group
Intervention type: OTHER
Intervention: Real-life epidemiological platform of lymphoma in France
Description: The REALYSA database will be described with the following characteristics:~* Number of patients included per month in total and according to subtype of lymphoma~* Number of patients in each region in total and according to subtype of lymphoma
Study NCT01868737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus rhamnosus GG and Bifidobacterium infantis'
Study NCT01868737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil
Study NCT06181188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive a combination of ketamine and midazolam for conscious sedation
Study NCT06181188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
Study NCT06181188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
Study NCT03696121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Injection
Description: Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
Study NCT03696121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
Study NCT01073618 — intervention group
Intervention type: DRUG
Intervention: voriconazole IV
Description: 6 mg/kg iv q 12 hours (loading) then maintenance
Study NCT02328664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible sigmoidoscopy or colonoscopy
Description: Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
Study NCT02057822 — intervention group
Intervention type: PROCEDURE
Intervention: Cytokins assay in tears
Study NCT01925742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum QUAD Assay for aneuploidy screening
Description: Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
Study NCT01925742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semiconductor MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
Study NCT01925742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical-based MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
Study NCT01925742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmony™ Test (Ariosa Diagnostics)
Description: Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
Study NCT04514146 — intervention group
Intervention type: OTHER
Intervention: Water-only fasting
Description: In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
Study NCT00962182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAN1
Description: 3-4 capsules/day at meals
Study NCT00962182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enzyme
Description: 3-4 capsules/day at meals
Study NCT00962182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAN1+gluten
Description: 3-4 capsules/day at meals plus 500 mg gluten b.i.d
Study NCT00139490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Program
Description: The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
Study NCT00139490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Group
Description: The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay.
Study NCT00139490 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Usual Care
Study NCT02761265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgery to correct spinal deformity
Study NCT02761265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: None (Asymptomatic group)
Description: Gait and balance testing performed, no treatment in this asymptomatic group
Study NCT02586545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared care
Study NCT00420290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kineret
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
Study NCT00420290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
Study NCT03910582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personalized frozen-thawed embryo transfer
Description: The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
Study NCT03910582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine frozen-thawed embryo transfer
Description: The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
Study NCT04014101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Study NCT04014101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is a selective VEGFR2 inhibitor.
Study NCT02760784 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early weight bearing
Description: The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
Study NCT01808014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nefopam
Description: The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
Study NCT02805569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: articulating stylet
Description: patient who intubated with articulating stylet
Study NCT02805569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional stylet
Description: patient who intubated with conventional stylet
Study NCT04576169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Debridement
Description: Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
Study NCT04576169 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo surgery
Description: Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
Study NCT04576169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic or Open Repair
Description: An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
Study NCT04576169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
Study NCT03263377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: The school feeding intervention
Description: The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
Study NCT03263377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: The school feeding intervention
Description: The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
Study NCT00054119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cositecan
Description: Given IV
Study NCT00054119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT05613335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
Description: Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
Study NCT05613335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
Description: Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
Study NCT01876199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intense follow up
Study NCT02807324 — intervention group
Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
Study NCT02423473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions
Study NCT02423473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions
Study NCT04364542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Description: The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
Study NCT04364542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Nerve Block
Description: The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
Study NCT06181188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
Study NCT02423473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite resin restoration (Filtek Supreme - 3M)
Description: Restorative procedure do treat tooth structure loss
Study NCT00512135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 units)
Description: Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
Study NCT00059683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cerclage
Description: Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
Study NCT01800877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vasopressors
Study NCT04364542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: Conventional arthroscopic rotator cuff repair.
Study NCT04364542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: Conventional arthroscopic rotator cuff repair.
Study NCT00623909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AvicennaTM class IV laser application
Description: AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
Study NCT02044276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: 6 mg
Study NCT00822029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSAMAX
Description: patient receiving one tablet (oral use) 70 mg Fosamax by week
Study NCT00822029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: patient receiving one tablet (oral use) placebo by week
Study NCT02044276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: 6 mg
Study NCT00765323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Implant
Description: 84 mg octreotide subcutaneous implant for 6 months
Study NCT01388621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study NCT00765323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR Depot
Description: Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
Study NCT02726009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT01195389 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group
Study NCT01477827 — intervention group
Intervention type: OTHER
Intervention: None - observational study
Study NCT01195389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group
Study NCT00552526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: Ketogenic diet is a very strict high fat diet